CRYSTALLINE FORM OF 4-[5-(PYRIDINE-4-YL)-1H-1,2,4-TRIAZOLE-3-YL]PYRIDINE-2-CARBONITRILE

Description

Technical Field

[0001] The present invention relates to a crystalline polymorph of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile and to a production method therefor.

Background Art

[0002] Compound (1), 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile, is known to serve as a drug which has a xanthine oxidase inhibitory action and which can lower serum uric acid level (Patent Document 1).

[0003] There have been reported several methods for producing the above compound (1). In one production method, methyl isonicotinate N-oxide is subjected to Reissert Henze reaction, to thereby form methyl 2-cyanoisonicotinate, which is transformed into a hydrazide, and the hydrazide is condensed with 4-cyanopyridine (Patent Document 1, Example 12). In another production method, isonicotinic acid N-oxide is transformed into a hydrazide, into which a cyano group is incorporated through Reissert Henze reaction, and the product is condensed with 4-cyanopyridine (Patent Document 1, Example 39). In an alternative production method, 4-cyanopyridine-N-oxide (starting material) is condensed with isonicotinic acid hydrazide, to thereby form a triazole ring, which is then protected (Patent Document 2) or non-protected (Patent Document 3), and a cyano group is incorporated into the product through Reissert Henze reaction, to thereby yield compound (1).

[0004] Meanwhile, crystalline polymorphism means such a condition that a compound formed of a unique molecule having a unique chemical composition exists in two or more crystal forms having different molecular arrangements. When a pharmaceutical compound is such a compound, pharmacological activity, solubility, bioavailability, stability, and the like of the compound are known to vary depending on the physicochemical properties intrinsic to the polymorph. Thus, when the useful pharmaceutical compound includes crystalline polymorphs, a compound of a crystal form which provides high utility is preferably produced.

Citation List

Patent Document

[0005] 

Patent Document 1: WO2003/064410

Patent Document 2: WO2005/009991

Patent Document 3: JP-A-2005-41802

Summary of the Invention

Problems to be Solved by the Invention

[0006] However, the aforementioned Patent Documents disclose production methods for 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile, but do not disclose crystalline polymorphism of the compound. The disclosed production methods are provided for the purpose of enhancement in yield and chemical purity. That is, these patent documents describe no crystallographic aspect of the compound.

[0007] Thus, an object of the present invention is to provide a pharmaceutically useful novel crystal form of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile, whose crystalline polymorphism has not yet been elucidated. Another object is to provide a production method therefor.

Means for Solving the problems

[0008] The present inventors have conducted extensive studies in order to solve the aforementioned problems, and have found that treating free 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile with an acid, to form a corresponding salt, treating the salt with a base, and neutralizing the base-treated product with an acid can yield type I crystals thereof. The inventors have also found that recrystallizing free 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile from an organic solvent can yield type II crystals thereof. The inventors have also found that storing free 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile under humidified conditions can yield a hydrate thereof.

[0009] Accordingly, the present invention provides the following [1] to [3].

[1] Type I crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile characterized by a powder X-ray diffractometry spectrum as shown in Figure 1 and exhibiting characteristic peaks in X-ray powder diffractometry at diffraction angles 2θ of about 10.1°, 16.0°, 20.4°, 25.7°, and 26.7°, wherein the powder X-ray diffraction spectrum refers to a spectrum measured by means of Mini Flex, product of Rigaku Corporation, using Cu as X-ray source.

[2] A method for producing type I crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile as recited in [1] above, the method comprising treating an acid salt of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile with a base and subsequently neutralizing the treated product with an acid.

[3] A pharmaceutical composition comprising the type I crystals as recited in [1] above, and a pharmaceutically acceptable carrier.

Effects of the Invention

[0010] The present invention enables provision of type I crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile, which are useful pharmaceuticals.

[0011] The present invention enables provision of methods for producing type I crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile.

[0012] In particular, the type I crystals thereof are more useful than the other crystal forms, from the viewpoints of industrial superiority, solubility, and crystal form stability.

Brief Description of the Drawings

[0013] 

[Fig. 1] An powder X-ray diffraction pattern of type I crystals.

[Fig. 2] An powder X-ray diffraction pattern of type II crystals.

[Fig. 3] An powder X-ray diffraction pattern of the hydrate.

[Fig. 4] Differential scanning calorimetry (DSC) pattern of type I crystals.

[Fig. 5] Differential scanning calorimetry (DSC) pattern of type II crystals.

[Fig. 6] Differential scanning calorimetry (DSC) (enlarged) pattern of type II crystals.

[Fig. 7] Differential scanning calorimetry (DSC) pattern of the hydrate.

[Fig. 8] Solubility test results of various crystal forms. Modes for Carrying Out the Invention

[0014] The present invention will next be described in detail.

[0015] Type I crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile (hereinafter referred to as compound (1)) are produced through treating an acid salt of compound (1) with a base and neutralizing the treated product with an acid.

[0016] Examples of the acid salt of compound (1) include inorganic acid salts such as hydrochloride, sulfate, and phosphate; and organic acid salts such as oxalate, malonate, succinate, acetate, and p-toluenesulfonate. Of these, the p-toluenesulfonate is preferred. These acid salts may be produced through any method disclosed in Patent Documents 1 to 3.

[0017] In a preferred mode of the base treatment of the acid salt of compound (1), a base is dissolved in a solvent, and the acid salt of compound (1) is added to the solution. Examples of the solvent which can solve the acid salt of compound (1) include protic solvents such as water, methanol, ethanol, isopropanol, 1-butyl alcohol, 2-methyl-1-propanol, 2-butanol, 2-methyl-2-propanol, and ethylene glycol. In use, these solvents may be mixed at any ratio, to thereby provide a mixed solvent. Among these solvents, a water-alcohol mixed solvent is preferred, with a water-ethanol (3 : 1 to 10 : 1) mixed solvent being more preferred.

[0018] No particular limitation is imposed on the amount, temperature, etc. of the aforementioned solvent, so long as the amount, temperature, etc. allow the acid salt of compound (1) to be dissolved therein.

[0019] Any base may be used in the base treatment of the acid salt of compound (1), so long as the base can render the solution of the acid salt of compound (1) to be weakly basic. Examples of the base include inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, trisodium phosphate, and tripotassium phosphate; and tertiary amines such as triethylamine and diisopropylethylamine. Of these, potassium carbonate and tripotassium phosphate are preferred.

[0020] These bases are preferably used in an amount of 2 to 5 mol, more preferably in an amount of 2 to 4 mol, with respect to 1 mol of the acid salt of compound (1).

[0021] For neutralizing the base-treated solution, an acid such as citric acid, hydrochloric acid, sulfuric acid, or phosphoric acid may be used. Of these, hydrochloric acid is preferred.

[0022] No particular limitation is imposed on the reaction temperature in neutralization with acid. However, the temperature is preferably -10°C to 30°C, more preferably 20 to 30°C.

[0023] Through neutralization with acid, type I crystals of compound (1) are precipitated. Type I crystals of compound (1) may be recovered though drying under reduced pressure with heating.

[0024] Type II crystals of compound (1) may be produced through recrystallization of compound (1) from an organic solvent. Examples of the recrystallization solvent include methanol, ethanol, 1-propanol, isopropanol, 1-butyl alcohol, 2-methyl-1-propanol, 2-butanol, 2-methyl-2-propanol, tetrahydrofuran, acetone, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, ethyl acetate, ether, diisopropyl ether, chloroform, hexane, cyclohexane, heptane, octane, benzene, toluene, and xylene. These solvents may be used singly or in combination of two or more species. The aforementioned recrystallization solvent is preferably an amide-type solvent, more preferably N,N-dimethylformamide. Recrystallization may be carried out by dissolving compound (1) at 60 to 160°C, preferably at 120 to 150°C, and then cooling the solution to 15 to 40°C, preferably to 20 to 30°C.

[0025] A hydrate of compound (1) may be produced by storing compound (1) under high humidity conditions (e.g., 20 to 30°C, relative humidity (RH): 85% to 97%). The storage time is at least 10 days.

[0026] The afore-yielded type I crystals of compound (1) exhibits characteristic peaks in a powder X-ray diffraction pattern at diffraction angles (2θ) of about 10.1°, 16.0°, 20.4°, 25.7°, and 26.7°. The powder X-ray diffraction spectral pattern is shown in Fig. 1.

[0027] The DSC pattern of Fig. 4 has an endothermic peak at about 327°C.

[0028] The afore-yielded type II crystals of compound (1) exhibits characteristic peaks in a powder X-ray diffraction pattern at diffraction angles (2θ) of about 9.9°, 16.3°, 18.2°, and 22.4°. The powder X-ray diffraction spectral pattern is shown in Fig. 2.

[0029] The DSC pattern of Fig. 5 has an endothermic peak at about 327°C, and that of Fig. 6 has an endothermic peak at about 273°C.

[0030] The hydrate of compound (1) exhibits characteristic peaks in a powder X-ray diffraction pattern at diffraction angles (2θ) of about 8.1°, 14.9°, 16.4°, 25.3°, 26.9°, and 27.6°. The powder X-ray diffraction spectral pattern is shown in Fig. 3.

[0031] The DSC pattern of Fig. 7 has endothermic peaks at about 107°C and 327°C.

[0032] The hydrate of compound (1) is preferably a monohydrate thereof.

[0033] In the present invention, the powder X-ray diffraction spectrum refers to a spectrum measured by means of Mini Flex (product of Rigaku Corporation) under the following conditions.

• X-ray source: Cu
• Goniometer: vertical
• Divergence slit: variable
• Scattering slit: 4.2 degree
• Receiving slit: 0.3 mm
• Scanning mode: continuous
• Scanning speed: 2°/min
• Scanning step: 0.02°
• Scanning axis: θ/2θ
• Scanning range: 3 to 60°

[0034] Endothermic peaks of DSC refer to those measured by means of DSC 220U (product of Seiko Instruments Inc.) under the following conditions.

• Temperature elevation rate: 10°C/min
• Atmosphere: nitrogen
• Measurement temperature range: 30 to 400°C

[0035] When the crystals of compound (1) are analyzed by means of the aforementioned apparatuses, crystal forms of compound (1) which have data and spectral patterns similar to one another are categorized into the same crystal form of the present invention. Also, when the type I crystals of compound (1) of the present invention, the type II crystals of compound (1), or the hydrate of compound (1) contains another crystal form in such a small amount as not to be detected through a routine measurement method, it is also categorized into the same crystal form.

[0036] Furthermore, physical property data of powder X-ray diffraction spectra, DSC, etc. might vary slightly due to variation in measurement factors such as crystal growth direction and particle size. Principally, the crystal form of compound (1) of the present invention should be determined by physical property data disclosed in the specification. However, as described above, this principle should not be strict, and slight variation in data of physical properties may be allowed. For example, an angle variation of ±0.5° in X-ray diffraction falling within an allowable range should be included in the scope of rights of the present invention.

[0037] Among crystal forms of compound (1), type I crystals of the present invention are particularly preferred, from the viewpoints of high water solubility and excellent thermal stability.

[0038] The type I crystal form of compound (1) of the present invention has excellent water-solubility and thermal stability. Thus, the crystal form can be processed into various pharmaceutical compositions by mixing with a pharmaceutically acceptable carrier. Such a pharmaceutical composition is preferably a solid preparation, particularly preferably a peroral solid preparation.

[0039] In production of a peroral solid preparation, crystals of compound (1) are mixed with an optional additive such as a vehicle, a binder, a disintegrator, a lubricant, a colorant, a coating agent, a wetting agent, a sugar coating agent, an antiseptic agent, a preservative, an antioxidant, or a flavoring agent/corrigent. The thus-obtained mixture is formed into preparations in the form of tablet, coated-tablet, granule, powder, capsule, or the like.

[0040] The pharmaceutical composition of the present invention is useful as a uric acid level reducing agent or a gout prophylactic/therapeutic agent.

Examples

[0041] The present invention will next be described in detail by way of Examples and Test Example, which should not be construed as limiting the invention thereto.

[0042] In the Examples, used are the following abbreviations: ¹H-NMR: proton nuclear magnetic resonance spectrum, DMSO-d₆: deuterated dimethylsulfoxide, Hz: hertz, J: coupling constant, s: singlet, dd: double doublet, and m: multiplet. The "NMR" refers to a 270 MHz nuclear magnetic resonance spectrum measured by use of TMS (tetramethylsilane) as an internal standard.

Example 1: Synthesis of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile p-toluenesulfonate

[0043] p-Toluenesulfonic acid monohydrate (6.62 g) was added to a water-2-butanol (10 : 1) mixture (55 mL). Subsequently, 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile (7.85 g) was added thereto at 80°C, and the resultant mixture was stirred at 80°C for 1 hour. The reaction mixture was cooled to room temperature, and the precipitated crystals were recovered through filtration. The crystals were washed with a water-2-butanol (10 : 1) mixture (40 mL) and dried at 80°C for 10 hours under reduced pressure, to thereby yield 12.6 g of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile p-toluenesulfonate. ¹H-NMR (DMSO-d₆) δ(ppm) : 2.29(s, 3H), 7.11(m, 2H), 7.48(dd, 2H, J=6.48, 1.62 Hz), 8.32-8.35(m, 3H), 8.57(dd, 1H, J=1.62, 0.81 Hz), 8.94-8.98(m, 3H)

Example 2: Preparation of type I crystals

[0044] Potassium carbonate (8.22 g) and 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile p-toluenesulfonate (10.0 g) were dissolved in a water-ethanol (9 : 1) mixture (80 mL). 6M hydrochloric acid (15 mL) was added to the solution, and the resultant mixture was stirred at 20°C for 5 hours. The precipitated crystals were recovered through filtration and washed with water (100 mL). The crystals were dried at 80°C for 23 hours under reduced pressure, to thereby yield 5.78 g of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile. The thus-obtained crystals exhibited a powder X-ray diffraction pattern shown in Fig. 1 and a DSC profile shown in Fig. 4, indicating that the crystals were type I crystals. ¹H-NMR (DMSO-d₆) δ(ppm): 8.02 (dd, 2H, J=4.59, 1.62 Hz), 8.32(dd, 1H, J=5.13, 1.62 Hz), 8.55(dd, 1H, J=1.62, 1.08 Hz), 8.80(dd, 2H, =4.59, 1.62 Hz), 8.93(dd, 1H, 5.13, 1.08 Hz) Melting point: 327°C

Example 3 (Comparative): Preparation of type II crystals

[0045] N,N-dimethylformamide (300 mL) was added to 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile (40.0 g), and the mixture was stirred at 150°C for 25 minutes. The thus-obtained solution was cooled to room temperature, and the precipitated crystals were recovered through filtration. The crystals were washed twice with water (200 mL) and dried overnight at 80°C under reduced pressure, to thereby yield 30.4 g of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile. The thus-obtained crystals exhibited a powde X-ray diffraction pattern shown in Fig. 2 and a DSC profile shown in Fig. 5, indicating that the crystals were type II crystals.
¹H-NMR (DMSO-d₆) δ(ppm): 8.02(dd, 2H, J=4.59, 1.62 Hz), 8.32(dd, 1H, J=5.13, 1.62 Hz), 8.55(dd, 1H, J=1.62, 1.08 Hz), 8.80(dd, 2H, J=4.59, 1.62 Hz), 8.93(dd, 1H, 5.13, 1.08 Hz) Melting point: 327°C

Example 4 (Comparative): Preparation of hydrate

[0046] 4-[5-(Pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile (about 2 g) was stored at 25°C and an RH of 97% for 14 days. The thus-obtained crystals exhibited a powder X-ray diffraction pattern shown in Fig. 3 and a DSC profile shown in Fig. 7, indicating that the crystals were in a hydrate form.
¹H-NMR (DMSO-d₆) δ(ppm): 8.02(dd, 2H, J=4.59, 1.62 Hz), 8.32(dd, 1H, J=5.13, 1.62 Hz), 8.55(dd, 1H, J=1.62, 1.08 Hz), 8.80(dd, 2H, J=4.59, 1.62 Hz), 8.93(dd, 1H, 5.13, 1.08 Hz) Melting point: 327°C

Test Example: Solubility test of various crystal forms

[0047] The water solubilities of type I crystals, type II crystals, and the hydrate of compound (1) were determined by calculating each sample concentration of its saturated solution determined through measuring absorbance. Fig. 8 shows the results. The water solubility of type I crystals was found to be 6.2 µg/mL, that of type II crystals 4.2 µg/mL, and that of the hydrate 1.9 µg/mL.

[0048] As is clear from Fig. 8, type I crystals and type II crystals have excellent water solubility. In particular, the water solubility of type I crystals is remarkably excellent.

Claims

1. Type I crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile characterized by a powder X-ray diffractometry spectrum as shown in Figure 1 and exhibiting characteristic peaks in X-ray powder diffractometry at diffraction angles 2θ of about 10.1°, 16.0°, 20.4°, 25.7°, and 26.7°, wherein the powder X-ray diffraction spectrum refers to a spectrum measured by means of Mini Flex, product of Rigaku Corporation, using Cu as X-ray source.

2. A method for producing type I crystals of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile as recited in claim 1, the method comprising treating an acid salt of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile with a base and subsequently neutralizing the treated product with an acid.

3. A pharmaceutical composition comprising the type I crystals as recited in claim 1, and a pharmaceutically acceptable carrier.

Ansprüche

1. Typ I-Kristalle von 4-[5-(Pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridin-2-carbonitril, gekennzeichnet durch ein Pulver-Röntgendiffraktometriespektrum, wie in Fig. 1 gezeigt, und die charakteristische Peaks in der Röntgenpulverdiffraktometrie bei Beugungswinkeln 2θ von etwa 10,1°, 16,0°, 20,4°, 25,7° und 26,7° zeigen, wobei sich das Pulver-Röntgendiffraktometriespektrum auf ein Spektrum bezieht, das mittels Mini Flex, Produkt der Rigaku Corporation, unter Verwendung von Cu als Röntgenquelle, gemessen wurde.

2. Verfahren zur Herstellung von Typ I-Kristallen von 4-[5-(Pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridin-2-carbonitril nach Anspruch 1, wobei das Verfahren das Behandeln eines Säuresalzes von 4-[5-(Pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridin-2-carbonitril mit einer Base und anschließendes Neutralisieren des behandelten Produkts mit einer Säure umfasst.

3. Pharmazeutische Zusammensetzung, umfassend die Typ I-Kristalle gemäß Anspruch 1 und einen pharmazeutisch akzeptablen Träger.

Revendications

1. Cristaux de type I de 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile caractérisés par un spectre de diffractométrie des rayons X par la technique des poudres tel que représenté sur la Figure 1 et présentant des pics caractéristiques dans le spectre de diffractométrie des rayons X par la technique des poudres à des angles de diffraction 2θ d'environ 10,1°, 16,0°, 20,4°, 25,7° et 26,7°, dans lesquels le spectre de diffraction des rayons X par la technique des poudres se réfère à un spectre mesuré au moyen d'un Mini Flex, produit de Rigaku Corporation, utilisant du Cu en tant que source de rayons X.

2. Procédé pour produire des cristaux de type I de 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile tels que définis dans la revendication 1, le procédé comprenant le traitement d'un sel acide de 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile avec une base et ensuite la neutralisation du produit traité avec un acide.

3. Composition pharmaceutique comprenant les cristaux de type I tels que définis dans la revendication 1, et un véhicule pharmaceutiquement acceptable.

Drawing